Biogen (BIIB) shares gained in premarket trading on Wednesday after the Alzheimer's drugmaker reported higher-than-expected Q3 2026 financials thanks mainly to its multiple sclerosis franchise and boosted its full-year earnings outlook. The Cambridge, Massachusetts-based b
Biogen (BIIB) shares gained in premarket trading on Wednesday after the Alzheimer’s drugmaker reported higher-than-expected Q3 2026 financials thanks mainly to its multiple sclerosis franchise and boosted its full-year earnings outlook.
The Cambridge, Massachusetts-based biotech added $2.8B in revenue for the quarter
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
